Enhanced glucose transport capacity of the intestinal epithelium, specifically enterocytes, is known to significantly contribute to systemic glucocorticoid (GC) - induced hyperglycemia. This effect is mainly dependent on overexpression of sodium glucose transporter 1 (Sglt1) and its enhanced activation by serum and glucocorticoid-regulated kinase 1 (Sgk1). In this work we aimed to investigate whether dietary intake affects intestinal glucocorticoid receptor (Nr3c1) signaling. In male C57/BL6 mice short term feeding of a Western diet (WD) resulted in increased glucocorticoid receptor expression in the ileum which was accompanied by an upregulation of the effector genes Sgk1 and sodium-hydrogen exchanger 3 (Nhe3) and liver receptor homologe 1 (Lrh1). The latter is known as the key regulator of intestinal corticosterone synthesis. Histological analysis showed that glucocorticoid receptor expression was mainly located in enterocytes. Intestinal Sgk1 expression remained significantly, about 2-fold, increased in mice fed a Western diet for 10 weeks, while Nr3c1, Lrh1 and Nhe3 expression levels were not significantly altered after long-term feeding. Further regulatory mechanisms were investigated in immortalized murine small intestine enterocyte cell line Mode-K: Stimulation with palmitic acid resulted in a significant upregulation of Sgk1 expression, while no effect was seen when exposed to oleic acid, arachidonic acid or docosahexanoic acid. In contrast to Sgk1, Nr3c1 expression was downregulated in Mode-K cells exposed to palmitic acid.

In conclusion, our data suggest that dietary fat intake might contribute to GC induced hyperglycemia by modulating intestinal Sgk1 expression in a glucocorticoid receptor-independent way.

Disclosure

B. Radlinger: Research Support; Self; Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp. S. Folie: Research Support; Self; Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp. J. Dobner: Research Support; Self; Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp. T. Adolph: None. C. Ress: Research Support; Self; Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp. F. Hornsteiner: Research Support; Self; Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp. S. Boentges: Research Support; Self; Boehringer Ingelheim International GmbH, Merck & Co., Inc. K. Salzmann: Research Support; Self; Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp. H. Tilg: None. S. Kaser: Research Support; Self; Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp.

Funding

Austrian Federal Ministry of Science, Research and Economy; National Foundation for Research, Technology and Development; Merck Sharp & Dohme Austria; Boehringer Ingelheim RCV

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.